Priya, Ewing’s sarcoma conqueror
Priya, an artistically gifted and academically bright 21-year old college student from a rural background, was diagnosed with an extremely rare and difficult-to-treat form of cancer in January 2015. Being a determined young lady, Priya herself took up the uphill task of fighting the cancer. Over the next two years, she underwent multiple chemotherapy sessions besides surgery and radiotherapy.
Due to the inherently difficult nature of this cancer, an effective treatment could not be achieved. The cancer not only persisted, but also spread to many internal organs including her bones. At this point, there appeared to be little hope for Priya.
DCGL carried out comprehensive genetic and cellular testing of the patient’s tumor and blood samples and selected a customized treatment for this patient.
Within 36 days of receiving DCGL-recommended treatment, the cancer was successfully prevented from spreading further. The existing cancer had also decreased significantly.
Deepak, melanoma conqueror
Deepak is a 57-year old father of two children who are currently studying abroad. When Deepak was diagnosed with Melanoma in the second half of 2016, he faced the dilemma of limited and expensive treatment options for this type of cancer, because surgery and radiotherapy failed to control the aggressive disease. The cancer had soon spread to multiple organs throughout the body.
In absence of any other treatment options that could help him overcome the disease, Deepak and his family even considered selling their house to pay for an expensive monoclonal antibody based immunotherapy treatment option, that was known to have only a very limited chance of succeeding.
DCGL carried out comprehensive genetic and cellular testing of the patient’s tumor and blood samples and selected a customized treatment for this patient.
Within 19 days of receiving DCGL-recommended treatment, the cancer had stopped progressing and had significantly decreased.
Harish, kidney cancer conqueror
Harish, a 53-year-old Public Service Officer and a fitness-enthusiast, was initially diagnosed with cancer in 2000. Following surgery and chemotherapy, the cancer appeared to have been cured. However, the disease recurred after 16 years, in 2016. At recurrence, the cancer was far more aggressive than before and had spread rapidly and extensively to other parts of the body.
Despite multiple rounds of radiotherapy and chemotherapy along with surgery, the cancer appeared uncontrollable. The cancer continued to spread at rapid rates and appeared at a new organ every few days. Considering the aggressiveness and chemo-resistance of this cancer, the patient was given less than a month to survive, and was advised palliative care for pain and symptom management.
DCGL carried out comprehensive genetic and cellular testing of the patient’s tumor and blood samples and selected a customized treatment for this patient.
DCGL-recommended treatment led to near complete elimination of the cancer from the body.
Rohini, leiomyosarcoma conqueror
Rohini, a 49- year old housewife, was diagnosed with a rare form of cancer (Leiomyosarcoma) in March 2016, after she noticed pain in legs along with swelling, that led to difficulty in walking. Unfortunately, there are not many standard treatment options for Leiomyosarcoma. Hence despite three lines of chemotherapy, which also had side-effects such as toxicity, the disease progressed to her liver and forearm.
Surgery and radiotherapy were ruled out due to the location of the cancer. Current medical knowledge and guidelines failed to provide any insight on how this cancer could be cured. Under these circumstances Rohini was advised to start palliative treatment, which would do little to rid the cancer or to prevent it from spreading. While the patient was otherwise healthy, her disease appeared to be incurable.
DCGL carried out comprehensive genetic and cellular testing of the patient’s tumor and blood samples and selected a customized treatment for this patient.
Within 30 days of receiving DCGL-recommended treatment, this ‘incurable’ form of cancer had stopped progressing. Within 90 days of same treatment, the cancer had also decreased in size.
Pradnya, breast cancer conqueror
Pradnya, a bright 22-year old student in the final year of her Master’s Degree first noticed a lump in her left breast in August 2016, which was later diagnosed as breast cancer. Between 2016 and 2017, she received multiple treatments, all of which failed to eliminate, reduce or even control the cancer.
The cancer was very aggressive and had spread to multiple organs in the patient’s body. At this point, Pradnya and her family were given the devastating news that she had less than a week to live, and was also advised palliative care.
DCGL carried out comprehensive genetic and cellular testing of the patient’s tumor and blood samples and selected a customized treatment for this patient.
Within 34 days of receiving DCGL-recommended treatment, the aggressive cancer had not only stopped spreading, but also significantly decreased throughout the body.
Girija, mouth cancer conqueror
Girija, a 65- year old hard-working lady from an economically weaker family, and a doting grandmother to her 5 grandchildren, was diagnosed with oral (cheek) cancer in April 2016. She underwent surgery for removal of the tumor, and also received chemotherapy. However, the cancer not only persisted, but also progressed and grew externally into an unmanageable mass.
The cancerous mass caused her great difficulty not only while eating and drinking, but also in conversing and caused not only severe pain, but also emotional distress. Due to limited treatment options for this type of cancer, there appeared to be no viable treatment strategy that would cure or even reduce the disease burden.
DCGL carried out comprehensive genetic and cellular testing of the patient’s tumor and blood samples and selected a customized treatment for this patient
Within 5 days of receiving DCGL-recommended treatment, the cancer decreased significantly. Within 30 days, there were only minimal signs that belied the previous extent of the cancer.
